Frequency of Incidental Cancer in Transurethral Prostate Resection Materials and Our Clinical Approach to These Patients; a Retrospective File Scan

Abstract

Transüretral Prostat Rezeksiyonu Materyallerindeki İnsidental Kanser Sıklığı ve Bu Hastalardaki Klinik Yaklaşımımız; Geriye Dönük Dosya Taraması

Abstract

ABSTRACT Aim: This study aims to determine the incidence of cancer in patients who underwent transurethral resection of the prostate (TUR-P) due to bladder outlet obstruction and to share our clinical approach to these patients at Niğde Ömer Halisdemir University Training and Research Hospital. Material and Method: The pathology reports of 650 TUR-P specimens from January 1, 2012, to December 31, 2017, were retrospectively screened. In the pathology results of the prostatic adenocarcinoma patients, the age, tumor stage and Gleason score (GS) were evaluated. Physical examination data and the serum total Prostate Specific Antigen (PSA) levels, as well as the radiological findings, were analyzed according to the hospital records. Results: After excluding nine patients with known prostate carcinoma there were 15 adenocarcinomas out of 641 patients (2.34%). The mean age was 72. Eleven patients were diagnosed as GS 6, and four patients were diagnosed with GS 7 prostate adenocarcinoma. Serum total PSA levels ranged from 1.56 to 9.22 ng/mL. T1a tumor was detected in 11 patients and T1b tumor in 4 patients. Conclusion: Considering the studies that reported incidental prostate cancer (IPC) rates in the PSA era, our rate is close to the lower limit. The application of primary therapies should not be avoided in patients with IPC after TUR-P.

Keywords

• insidental prostat kanseri; transüretral rezeksiyon; PSA

References

1. 1. Bostwick D, Cheng L. Chapter 9: Neoplasms of the prostate. In: Bostwick D, ed. Urologic surgical pathology 2nd ed. Portland: Mosby Elsevier; 2008:410–3. 2. Otto B, Barbieri C, Lee R, Te AE, Kaplan SA, Robinson B, et al. Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Adv Urol 2014;6272–90. 3. Adolfsson J. The management of category T1a-T1b (incidental) prostate cancer: can we predict who needs treatment? Eur Urol 2008;54(1):16–8. 4. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–42. 5. Augustin H, Erbersdobler A, Graefen M, Fernandez S, Palisaar J, Huland H, et al. Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones. Prostate 2003;55:48–54. 6. Lilja H. A kallikrein like serum protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899–903. 7. Morote J, Lopez M, Encabo G, de Torres IM. Effect of inflammation and benign prostatic enlargement on total and free serum prostate specific antigen. Eur Urol 2000;37:537–40. 8. Malkoç E, Ateş F, Uğuz S, Dursun F, Karademir AK, Adayener C, et al. Histolojik olarak kanıtlanmış kronik prostatit ile PSA dansitesi arasındaki ilişki. Gülhane Tıp Derg 2013;55:18–21. 9. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000;55:791–5. 10. Tombal B, De Visccher L, Cosyns JP, Lorge F, Opsomer R, Wese FX, et al. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1aT1b prostate cancers, BJU Int 1999;84(9):1015–20. 11. Mai KT, Isotalo PA, Green J, Perkins DG, Morash C, Collins JP. Incidental prostatic adenocarcinomas and putative premalignant lesions in TURP specimens collected before and after the introduction of prostrate-specific antigen screening, Arch Pathol Lab Med 2000;124(10):1454–6. 12. Güvendi FG, Toyran T, Bağcıoğlu M, Kılıç Ö, Adalı Y. The incidence and significance of incidental prostate carcinoma in transurethral resection (TUR-P) materials between 2014 and 2016 at Our Center, Medical Sciences (NWSAMS) 2018;13(2):19–22. 13. Yoo C, Oh CY, Kim SJ, Kim SI, Kim YS, Park JY, et al. Preoperative clinical factors for diagnosis of incidental prostate cancer in the era of tissue ablative surgery for benign prostatic hyperplasia: A Korean multi-center review. Korean J Urol 2012;53(6):391–5. 14. Khan MA, Shah HU, Gul M, Qayyum A. Frequency of incidentally diagnosed prostate carcinoma in transurethrally resected prostate specimens. J Postgrad Med Inst 2017;31(4):357–60. 15. Trpkov K1, Thompson J, Kulaga A, Yilmaz A. How much tissue sampling is required when unsuspected minimal prostate carcinoma is identified on transurethral resection? Arch Pathol Lab Med 2008;132(8):1313–6. 16. Varghese J, Kuruvilla MP, Mehta N, Rathore RS, Babu M, Bansal B, et al. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India. Asian Pac J Cancer Prev 17(4), 2255–58. 17. Thapa N, Shris S, Pokharel N, Tambay YG, Kher YR, Acharya S. Incidence of carcinoma prostate in transurethral resection specimen in a teaching hospital of Nepal. Journal of Lumbini Medical College 2016;4(2):77–9. 18. İhvan AN, Ediz C, Koç N. İnsidental Prostat Kanserine Eşlik Eden Histopatolojik Parametreler. Bulletin of Urooncology 2016;15:48–51. 19. Aslan G, Mammadov E, Kizer O, Tuna B, Yörükoğlu K. Biyopside yüksek dereceli prostatik intraepitelyal neoplazi veya malignite kuşkulu odak varlığında tur-p sonuçları. DEÜ Tıp Fakültesi Dergisi 2010;24(3):113–7. 20. Karadağ MA, Çeçen K, Demir A, Bağcıoğlu M, Kocaaslan R, Sofikerim M. Prostat kanserinde fokal tedavi alternatifleri. Kafkas J Med Sci 2015;5(1):18–24. 21. Palisaar JR, Wenske S, Sommerer F, Hinkel A, Noldus N. Open radical retropubic prostatectomy gives favourable surgical and functional outcomes after transurethral resection of the prostate. BJU International 2009;104:611–5.